form8-k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
October
2, 2008 (October 2, 2008)
Rite
Aid Corporation
(Exact
name of registrant as specified in its charter)
|
Delaware
|
1-5742
|
23-1614034
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
30
Hunter Lane, Camp Hill, Pennsylvania 17011
(Address
of principal executive offices, including zip code)
(717)
761-2633
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 2.02. Results of
Operations and Financial Condition.
On October 2, 2008, Rite Aid
Corporation (the "Company") provided the following information as part of an
investor presentation by management. The Company stated that as
of August 30, 2008, $1,013.0 million was outstanding under the Company's senior
secured revolving credit facility, and as of such date, the Company had
additional available borrowing capacity of approximately $549 million under the
revolving credit facility. As of August 30, 2008, the Company had
lease financing obligations outstanding of $225.7 million. The
Company also stated that it had capital expenditures of approximately $178.5
million and proceeds from sale and leaseback transactions of approximately $94.1
million in the thirteen weeks ended August 30, 2008. These capital expenditures
included $56.1 million of integration-related capital expenditures
and $25.3 million of prescription file buys. In addition, the
Company stated that for the thirteen weeks ended August 30, 2008, the Company
had private label penetration of 11.6% of front-end sales and generic drug
penetration of 66.9% of prescription sales at its Brooks Eckerd
stores.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereto
duly authorized.
|
Date: October
2, 2008
|
|
By:
|
/s/
Robert B. Sari
|
|
|
|
|
Name:
|
Robert
B. Sari
|
|
|
|
Title:
|
Executive
Vice President,
General
Counsel and Secretary
|